Investor Ideas Adds Recent
IPO’s - Biotech (NYSE: $ADCT) (Nasdaq: $AYLA) (Nasdaq: $LYRA), Cloud (Nasdaq: $KC)
and Gaming (Nasdaq: $GAN)
Point Roberts WA, Delta BC, May 22, 2020 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
leading investor resource announces its weekly roundup of stocks added to its
global stock directories, including biotech, cloud and gaming.
The latest company additions are all May IPO’s and
are listed on the biotech, cloud and gaming directories.
ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused
biotechnology company pioneering the development and commercialization of
highly potent and targeted antibody drug conjugates (ADCs) for patients
suffering from hematological malignancies and solid tumors. The Company
develops ADCs by applying its decades of experience in this field and using
next-generation pyrrolobenzodiazepine (PBD) technology to which ADC
Therapeutics has proprietary rights for its targets. Strategic target selection
for PBD-based ADCs and substantial investment in early clinical development
have enabled ADC Therapeutics to build a deep clinical and research pipeline of
therapies for the treatment of hematological and solid tumor cancers with
significant unmet need. The Company has multiple PBD-based ADCs in ongoing
clinical trials, ranging from first in human to pivotal Phase 2 clinical
trials, in the USA and Europe, and numerous preclinical ADCs in development.
Ayala Pharmaceuticals, Inc. (NasdaqGS:AYLA) is a clinical-stage
biopharmaceutical company dedicated to developing targeted cancer therapies for
people living with genetically defined cancers. Ayala is broadly developing its
product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors,
with clinical and preclinical studies underway in both solid tumors (AL101) and
hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is
currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing
Notch activating mutations
Lyra Therapeutics, Inc. (NasdaqGM:LYRA) is a clinical-stage therapeutics
company focused on the development and commercialization of novel integrated
drug and delivery solutions for the localized treatment of patients with ear,
nose and throat diseases. The company’s proprietary technology platform,
XTreo™, is designed to precisely and consistently deliver medicines directly to
the affected tissue for sustained periods with a single administration. The
company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable
polymeric matrices designed to be administered in a brief, non-invasive,
in-office procedure and intended to deliver up to six months of continuous drug
therapy to the sinonasal passages for the treatment of chronic rhinosinusitis,
or CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone
furoate, which is the active ingredient in various FDA-approved drugs and has a
well-established efficacy and safety profile. CRS is an inflammatory disease of
the paranasal sinuses which leads to debilitating symptoms and significant
morbidities and affects approximately 14 million people in the United States.
The company is advancing LYR-210 as a potential preferred alternative to
surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed
medical management. In its Phase 1 clinical trial, LYR-210 met its primary
safety endpoint, and it was observed that patients generally experienced
significant and rapid, clinically meaningful and durable improvement in SNOT-22
scores, an established patient symptom severity scale, through week 25, which
was the end of the trial. The company is also developing LYR-220 for use in CRS
patients who have an enlarged nasal cavity due to sinus surgery but continue to
require treatment to manage CRS symptoms. Beyond CRS, the company believes its
XTreo platform has potential applications in other disease areas, which it is
actively exploring to further broaden the platform’s therapeutic potential.
Kingsoft Cloud Holdings Ltd (NasdaqGS:KC) is the largest independent cloud service provider in
China. Kingsoft Cloud has built a comprehensive and reliable cloud platform
consisting of extensive cloud infrastructure, cutting-edge cloud products and
well-architected industry-specific solutions across public cloud, enterprise
cloud and AIoT cloud services. As an independently operated company, Kingsoft
Cloud is able to fully mobilize its resources towards the innovation of its
business models and provide high-quality services to all kinds of businesses
and organizations. With its focus squarely on its cloud business, Kingsoft
Cloud is able to avoid potential conflicts of interest with its customers and
enhance its neutral position, which in turn gains additional trust from more
and more customers.
GAN Ltd (NasdaqGS:GAN) is a leading business-to-business supplier of internet
gambling software-as-a-service solutions predominantly to the U.S. land-based
casino industry. GAN has developed a proprietary internet gambling enterprise
software system, GameSTACK™, which it licenses to land-based casino operators
as a turnkey technology solution for regulated real-money internet gambling,
encompassing internet gaming, internet sports gaming and virtual Simulated
Gaming.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a
recognized news source publishing third party news and press releases, research
and our own original financial content. We were one of the first retail
investor sites to cover renewable energy and cleantech stocks at investorideas.com
and our domain Renewableenergystocks.com. We were also one of the most well-
known and cited defense stock sites, featuring our domain
Homelanddefensestocks.com at its peak.
We follow the money for
investors as sector sentiment shifts and technology disrupts. Our mission is to
provide investor ideas with breaking news, resources, industry articles and
interviews with leading experts.
Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking
at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy and more. Investor Idea's original branded content includes the
following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis
News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the
sectors we cover use our news and content services to tell their story to interested investors.
Paid for content is disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media
services at Investorideas.com
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment